Emerging anti-inflammatory strategies for COPD

European Respiratory Journal

Volumn 40, Issue 3, 2012, Pages 724-741

  Cazzola, Mario ^a,b   Page, Clive P ^d   Calzetta, Luigino ^b   Matera, M Gabriella ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Targeted therapy; Therapeutic interventions; Treatment of chronic obstructive pulmonary disease

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; ABX CXCL8; ADALIMUMAB; ADENOSINE A2A RECEPTOR AGONIST; ANALGESIC, ANTIINFLAMMATORY, ANTIRHEUMATIC AND ANTIGOUT AGENTS; ANTIINFLAMMATORY AGENT; BIMOSIAMOSE; CERTOLIZUMAB PEGOL; CILOMILAST; DILMAPIMOD; ETANERCEPT; GOLIMUMAB; GSK 256066; GW 328267X; I KAPPA B; INFLIXIMAB; MACROLIDE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PGX 100; PH 797804; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PROTEIN INHIBITOR; REGADENOSON; ROFLUMILAST; UK 432097; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; CELL MIGRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENTERITIS; ENZYME INHIBITION; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG INJURY; NAUSEA; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; WEIGHT REDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMOKINES; DISEASE PROGRESSION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MICE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84865823980     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00213711     Document Type: Review

References (153)

1. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011; 378: 1015-1026.
2. Barnes PJ. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004; 1: 264-268.
3. Matera MG, Cazzola M. New anti-inflammatory approaches in COPD. Drug Discov Today: Ther Strat 2004; 1: 335-343. (Pubitemid 40197612)
4. Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 2003; 63: 2575-2594. (Pubitemid 37491561)
5. Martorana PA, Beume R, Lucattelli M, et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005; 172: 848-853. (Pubitemid 41369068)
6. Boswell-Smith V, Cazzola M, Page CP. Are phosphodiesterase 4 inhibitors just more theophylline? J Allergy Clin Immunol 2006; 117: 1237-1243. (Pubitemid 43795733)
7. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. Lancet 2009; 374: 684-695.
8. Diamant Z, Spina D. PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease. Pulm Pharmacol Ther 2011; 24: 353-360.
9. Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir Res 2011; 12: 18.
10. Bateman ED, Rabe KF, Calverley PM, et al. Roflumilast with long-acting β2-agonists for COPD: influence of exacerbationhistory. Eur Respir J 2011; 38: 553-560.
11. Lamontagne S, Meadows E, Luk P, et al. Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res 2001; 920: 84-96. (Pubitemid 33086782)
12. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-a responses. Proc Natl Acad Sci USA 2002; 99: 7628-7633. (Pubitemid 34568742)
13. Burgin AB, Magnusson OT, Singh J, et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 2010; 28: 63-70.
14. Danto S, Wei GC, Gill J. A randomized, double-blind, placebo-controlled, parallel group, six-week study of the efficacy and safety of tofimilast dry powder for inhalation (DPI) in adults with COPD. Am J Respir Crit Care Med 2007; 175: A131.
15. Gutke HJ, Guse JH, Khobzaoui M, et al. AWD-12-281(inhaled) (elbion/GlaxoSmithKline). Curr Opin Investig Drugs 2005; 6: 1149-1158.
16. Vestbo J, Tan L, Atkinson G, et al. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J 2009; 33: 1039-1044.
17. Boswell-Smith V, Spina D, Oxford AW, et al. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6- trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H- pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6- diisopropylphenoxy)-9,10- dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]. J Pharmacol Exp Ther 2006; 318: 840-848. (Pubitemid 44061259)
18. Séguin RM, Ferrari N. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2009; 18: 1505-1517.
19. Sullivan GW. Adenosine A2A receptor agonists as anti-inflammatory agents. Curr Opin Investig Drugs 2003; 4: 1313-1319. (Pubitemid 38100576)
20. Haskó G, Linden J, Cronstein B, et al. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008; 7: 759-770.
21. Flamand N, Boudreault S, Picard S, et al. Adenosine, a potent natural suppressor of arachidonic acid release and leukotriene biosynthesis in human neutrophils. Am J Respir Crit Care Med 2000; 161: S88-S94. (Pubitemid 30129423)
22. Trevethick MA, Mantell SJ, Stuart EF, et al. Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutions. Br J Pharmacol 2008; 155: 463-474.
23. Thomas GS, Tammelin BR, Schiffman GL, et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 2008; 15: 319-328.
24. El-Tayeb A, Iqbal J, Behrenswerth A, et al. Nucleoside-5′- monophosphates as prodrugs of adenosine A2A receptor agonists activated by ecto-5′-nucleotidase. J Med Chem 2009; 52: 7669-7677.
25. Samsel M, Dzierzbicka K. Therapeutic potential of adenosine analogues and conjugates. Pharmacol Rep 2011; 63: 601-617.
26. Geng JG. Directional migration of leukocytes: their pathological roles in inflammation and strategies for development of antiinflammatory therapies. Cell Res 2001; 11: 85-88. (Pubitemid 33677212)
27. Cheung LS, Raman PS, Balzer EM, et al. Biophysics of selectin-ligand interactions in inflammation and cancer. Phys Biol 2011; 8: 015013.
28. Barnes PJ. COPD: is there light at the end of the tunnel? Curr Opin Pharmacol 2004; 4: 263-272. (Pubitemid 38585311)
29. Davenpeck KL, Berens KL, Dixon RA, et al. Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: preferential activity against neutrophil adhesion in vitro. J Allergy Clin Immunol 2000; 105: 769-775. (Pubitemid 30226452)
30. Radi ZA, Caverly JM, Dixon RA, et al. Effects of the synthetic selectin inhibitor TBC1269 on tissue damage during acute Mannheimia haemolytica-induced pneumonia in neonatal calves. Am J Vet Res 2001; 62: 17-22. (Pubitemid 32098899)
31. Bock D, Beeh K, Beier J, et al. Safety and efficacy of the inhaled pan-selectin antagonist bimosiamose in patients with COPD. Eur Respir J 2007; 30: Suppl. S1, 613s.
32. Watz H, Bock D, Meyer M, et al. Inhaled pan-selectin antagonist bimosiamose in COPD: A double-blind, randomized, placebo-controlled phase II study. Eur Respir J 2011; 38: Suppl. S5, 818s-819s.
33. Bedard PW, Kaila N. Selectin inhibitors: a patent review. Expert Opin Ther Pat 2010; 20: 781-793.
34. Matera MG, Calzetta L, Cazzola M. TNF-α inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm Pharmacol Ther 2010; 23: 121-128.
35. van der Vaart H, Koeter GH, et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 465-469.
36. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 926-934. (Pubitemid 46684703)
37. Dentener MA, Creutzberg EC, Pennings H-J, et al. Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. Respiration 2008; 76: 275-282.
38. Suissa S, Ernst P, Hudson M. TNF-α antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2008; 21: 234-238.
39. Mahler DA, Huang S, Tabrizi M, et al. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004; 126: 926-934. (Pubitemid 39258050)
40. Yang XD, Corvalan JR, Wang P, et al. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol 1999; 66: 401-410. (Pubitemid 29439246)
41. Proudfoot AE, Handel TM, Johnson Z, et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 2003; 100: 1885-1890. (Pubitemid 36254543)
42. D'Elios MM, Del Prete G, Amedei A. Interfering with chemokines and chemokine receptors as potential new therapeutic strategies. Expert Opin Ther Patents 2008; 18: 309-325.
43. Donnelly LE, Rogers DF. Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs 2003; 63: 1973-1998. (Pubitemid 37229086)
44. Barnes PJ. The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2009; 41: 631-638.
45. Koelink PJ, Overbeek SA, Braber S, et al. Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. Pharmacol Ther 2012; 133: 1-18.
46. Holz O, Khalilieh S, Ludwig-Sengpiel A, et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 2010; 35: 564-570.
47. Lazaar AL, Sweeney LE, MacDonald AJ, et al. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol 2011; 72: 282-293.
48. Pease JE, Sabroe I. The role of interleukin-8 and its receptors in inflammatory lung disease. Implications for therapy. Am J Respir Med 2002; 1: 19-25. (Pubitemid 37038920)
49. Saetta M, Mariani M, Panina-Bordignon P, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 165: 1404-1409. (Pubitemid 34522945)
50. Zhang J, Patel JM. Role of the CX3CL1-CX3CR1 axis in chronic inflammatory lung diseases. Int J Clin Exp Med 2010; 3: 233-244.
51. McComb JG, Ranganathan M, Liu XH, et al. CX3CL1 up-regulation is associated with recruitment of CX3CR1+ mononuclear phagocytes and T lymphocytes in the lungs during cigarette smoke-induced emphysema. Am J Pathol 2008; 173: 949-961.
52. Ning W, Li CJ, Kaminski N, et al. Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 2004; 101: 14895-14900. (Pubitemid 39410771)
53. Mionnet C, Buatois V, Kanda A, et al. CXCR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung. Nat Med 2010; 16: 1305-1313.
54. Owen C. Chemokine receptors in airway disease: which receptors to target? Pulm Pharmacol Ther 2001; 14: 193-202. (Pubitemid 32619924)
55. Horvath C, Welt FG, Nedelman M, et al. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ Res 2002; 90: 488-494. (Pubitemid 34633920)
56. Xia M, Sui Z. Recent developments in CCR2 antagonists. Expert Opin Ther Pat 2009; 19: 295-303.
57. Edwards MR, Bartlett NW, Clarke D, et al. Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 2009; 121: 1-13.
58. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002; 109: S81-S96.
59. Delhase M, Li N, Karin M. Kinase regulation in inflammatory response. Nature 2000; 406: 367-368.
60. Suzuki J, Ogawa M, Muto S, et al. Novel IκB kinase inhibitors for treatment of nuclear factor-κB -related diseases. Expert Opin Investig Drugs 2011; 20: 395-405.
61. Keslacy S, Tliba O, Baidouri H, et al. Inhibition of tumor necrosis factor-α-inducible inflammatory genes by interferon-γ is associated with altered nuclear factor-κB transactivation and enhanced histone deacetylase activity. Mol Pharmacol 2007; 71: 609-618. (Pubitemid 46147925)
62. Goto K, Chiba Y, Misawa M. IL-13 induces translocation of NF-κB in cultured human bronchial smooth muscle cells. Cytokine 2009; 46: 96-99.
63. Catley MC, Sukkar MB, Chung KF, et al. Validation of the anti-inflammatory properties of small-molecule IκB kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle. Mol Pharmacol 2006; 70: 697-705. (Pubitemid 44092330)
64. Gill JS, Zhu X, Moore MJ, et al. Effects of NFκB decoy oligonucleotides released from biodegradable polymer microparticles on a glioblastoma cell line. Biomaterials 2002; 23: 2773-2781. (Pubitemid 34465737)
65. Pelaia G, Cuda G, Vatrella A, et al. Mitogen-activated protein kinases and asthma. J Cell Physiol 2005; 202: 642-653. (Pubitemid 40175839)
66. Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38 MAPK in COPD. Eur Respir J 2008; 31: 62-69.
67. Stellato C. Post-transcriptional and nongenomic effects of glucocorticoids. Proc Am Thorac Soc 2004; 1: 255-263.
68. Barnes PJ. Novel signal transduction modulators for the treatment of airway diseases. Pharmacol Ther 2006; 109: 238-245. (Pubitemid 41740824)
69. Shieven GL. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem 2005; 5: 921-928.
70. Chopra P, Kanoje V, Semwal A, et al. Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases. Expert Opin Investig Drugs 2008; 17: 1411-1425.
71. Chung KF. p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 2011; 139: 1470-1479.
72. Pettus LH, Wurz RP. Small-molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: novel structures and developments during 2006-2008. Curr Top Med Chem 2008; 8: 1452-1467.
73. Branger J, Van den Blink B, Weijer S, et al. Antiinflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 2002; 168: 4070-4077. (Pubitemid 34298414)
74. Schreiber S, Feagan B, D'Haens G, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 325-334. (Pubitemid 43343889)
75. Singh D, Smyth L, Borrill Z, et al. A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol 2010; 50: 94-100.
76. Tan E, Jones I, Tweedy S, et al. The novel oral p38 inhibitor, PH-797804, inhibits inhaled lipopolysaccharide (LPS)-induced airway and systemic inflammatory markers in healthy subjects. Am J Respir Crit Care Med 2011; 183: A2554.
77. Barnes N, Pavord I, Maden C, et al. Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD. Eur Respir J 2009; 34: Suppl. S3, 648s.
78. MacNee W, Allan R, Jones I, et al. Arandomised, placebo controlled trial of 6 weeks' treatmentwith a novel oral p38 inhibitor in patients with COPD. Eur Respir J 2010; 36: Suppl. S4, 718s.
79. Zhang J, Shen B, Lin A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol Sci 2007; 28: 286-295. (Pubitemid 46818466)
80. Perry JJ, Harris RM, Moiani D, et al. p38a MAP kinase C-terminal domain binding pocket characterized by crystallographic and computational analyses. J Mol Biol 2009; 391: 1-11.
81. Millan DS, Bunnage ME, Burrows JL, et al. Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J Med Chem 2011; 54: 7797-7814.
82. Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol 2009; 21: 317-324.
83. Duraisamy S, Bajpai M, Bughani U, et al. MK2: a novel molecular target for anti-inflammatory therapy. Expert Opin Ther Targets 2008; 12: 921-936.
84. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657. (Pubitemid 34579158)
85. Thomas MJ, Smith A, Head DH, et al. Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. Eur J Immunol 2005; 35: 1283-1291. (Pubitemid 40542236)
86. Sapey E, Stockley JA, Greenwood H, et al. Behavioural and structural differences in migrating peripheral neutrophils from patients with COPD. Am J Respir Crit Care Med 2011; 183: 1176-1186.
87. Marwick JA, Chung KF, Adcock IM. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease. Ther Adv Respir Dis 2010; 4: 19-34.
88. Kulkarni S, Sitaru C, Jakus Z, et al. PI3Kβ plays a critical role in neutrophil activation by immune complexes. Sci Signal 2011; 4: ra23.
89. Ghigo A, Damilano F, Braccini L, et al. PI3K inhibition in inflammation: toward tailored therapies for specific diseases. Bioessays 2010; 32: 185-196.
90. Doukas J, Eide L, Stebbins K, et al. Aerosolized phosphoinositide 3-kinase γ/δ inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl) pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2009; 328: 758-765.
91. Reutershan J, Saprito MS, Wu D, et al. Phosphoinositide-3 kinase c required for LPS-induced transepithelial neutrophil trafficking in the lung. Eur Respir J 2010; 35: 1137-1147.
92. Maus UA, Backi M, Winter C, et al. Importance of phosphoinositide 3-kinase γ in the host defense against pneumococcal infection. Am J Respir Crit Care Med 2007; 175: 958-966. (Pubitemid 46684707)
93. Crooks SW, Stockley RA. Leukotriene B4. Int J Biochem Cell Biol 1998; 30: 173-178. (Pubitemid 28264189)
94. Hicks A, Monkarsh SP, Hoffman AF, et al. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Exp Opin Invest Drugs 2007; 16: 1909-1920. (Pubitemid 351403723)
95. Corhay JL, Henket M, Nguyen D, et al. LTB4 contributes to exhaled breath condensate and sputum neutrophil chemotaxis in COPD. Chest 2009; 136: 1047-1054.
96. Profita M, Sala A, Riccobono L, et al. 15(S)-HETE modulates LTB4production and neutrophil chemotaxis in chronic bronchitis. Am J Physiol Cell Physiol 2000; 279: C1249-C1258.
97. Devchand PR, Keller H, Peters JM, et al. The PPARα-leukotriene B4 pathway to inflammation control. Nature 1996; 384: 39-43.
98. Grönke L, Beeh KM, Cameron R, et al. Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2008; 21: 409-417.
99. Hicks A, Goodnow R Jr, Cavallo G, et al. Effects of LTB4 receptor antagonism on pulmonary inflammation in rodents and nonhuman primates. Prostaglandins Other Lipid Mediat 2010; 92: 33-43.
100. Kilfeather S. 5-Lipoxygenase inhibitors for the treatment of COPD. Chest 2002; 121: Suppl. S, 197S-200S.
101. Berger W, De Chandt MT, Cairns CB. Zileuton: clinical implications of 5-lipoxygenase inhibition in severe airway disease. Int J Clin Pract 2007; 61: 663-676. (Pubitemid 46449830)
102. Gompertz S, Stockley RA. A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest 2002; 122: 289-294. (Pubitemid 34754176)
103. Bernstein JA, Liu N, Knorr BA, et al. MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease. Respir Med 2011; 105: 392-401.
104. Woodruff PG, Albert RK, Bailey WC, et al. Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. COPD 2011; 8: 21-29.
105. Belvisi MG, Mitchell JA. Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. Br J Pharmacol 2009; 158: 994-1003.
106. van Bilsen M, van Nieuwenhoven FA. PPARs as therapeutic targets in cardiovascular disease. Expert Opin Ther Targets 2010; 14: 1029-1045.
107. Narala VR, Adapala RK, Suresh MV, et al. Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-α agonist. J Biol Chem 2010; 285: 22067-22074.
108. Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor γ agonists as therapy for chronic airway inflammation. Eur J Pharmacol 2006; 533: 101-109. (Pubitemid 43340008)
109. Milam JE, Keshamouni VG, Phan SH, et al. PPAR-γ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008; 294: L891-L901.
110. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170: 1191-1201.
111. Velayudhan J, Haran AC, Wright CD. The non-thiazolidinedione PPARγ ligand, GW1929 displays anti-inflammatory in poly(I:C)-induced air-liquid interface human bronchial epithelial cells. Am J Respir Crit Care Med 2011; 183: A2827.
112. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
113. Murphy DM, Forrest IA, Curran D, et al. Macrolide antibiotics and the airway: antibiotic or non-antibiotic effects? Expert Opin Investig Drugs 2010; 19: 401-414.
114. Cazzola M, Matera MG, Blasi F. Macrolide and occult infection in asthma. Curr Opin Pulm Med 2004; 10: 7-14. (Pubitemid 38045895)
115. Altenburg J, de Graaff CS, van der Werf TS, et al. Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respiration 2011; 81: 67-74.
116. Desaki M, Okazaki H, Sunazuka T, et al. Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kB activation. Antimicrob Agents Chemother 2004; 48: 1581-1585. (Pubitemid 38544362)
117. Jang YJ, Kwon HJ, Lee BJ. Effect of clarithromycin on rhinovirus-16 infection in A549 cells. Eur Respir J 2006; 27: 12-19. (Pubitemid 43092661)
118. Tsai WC, Rodriguez ML, Young KS. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med 2004; 170: 1331-1339. (Pubitemid 39657198)
119. Ivetić Tkalcević V, Bosnjak B, Hrvacić B, et al. Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. Eur J Pharmacol 2006; 539: 131-138.
120. Nakanishi Y, Kobayashi D, Asano Y, et al. Clarithromycin prevents smoke-induced emphysema in mice. Am J Respir Crit Care Med 2009; 179: 271-278.
121. Parnham MJ, Culic O, Erakovic V. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol 2005; 517: 132-143. (Pubitemid 40916224)
122. Marjanović N, Bosnar M, Michielin F, et al. Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. Pharmacol Res 2011; 63: 389-397.
123. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139-1147.
124. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689-698.
125. Fecik RA, Nguyen PL, Venkatraman L. Approaches to the synthesis of immunolides: selective immunomodulatory macrolides for cystic fibrosis. Curr Opin Drug Discov Devel 2005; 8: 741-747. (Pubitemid 41659402)
126. Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J 2010; 74: 818-826.
127. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax 2006; 61: 729-734. (Pubitemid 44211783)
128. Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 2003; 24: 225-248. (Pubitemid 36207079)
129. Wright JL, Zhou S, Preobrazhenska O, et al. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med 2011; 183: 50-58.
130. Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest 2007; 132: 1764-1771.
131. Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med 2009; 9: 32.
132. Bartziokas K, Papaioannou AI, Minas M, et al. Statins and outcome after hospitalization for COPD exacerbation: a prospective study. Pulm Pharmacol Ther 2011; 24: 625-631.
133. Barnes PJ. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 2010; 120: 76-85.
134. Biswas S, Rahman I. Modulation of steroid activity in chronic inflammation: a novel anti-inflammatory role for curcumin. Mol Nutr Food Res 2008; 52: 987-994.
135. Webster JI, Carlstedt-Duke J. Involvement of multidrug resistance proteins (MDR) in the modulation of glucocorticoid response. J Steroid Biochem Mol Biol 2002; 82: 277-288. (Pubitemid 36187398)
136. Nobili S, Landini I, Giglioni B, et al. Pharmacological strategies for overcomingmultidrug resistance. Curr Drug Targets 2006; 7: 861-879.
137. Hoi AY, Iskander MN, Morand EF. Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases. Inflamm Allergy Drug Targets 2007; 6: 183-190. (Pubitemid 47455787)
138. Vassilakopoulos T, Roussos C, Zakynthinos S. Is loaded breathing an inflammatory stimulus? Curr Opin Crit Care 2005; 11: 1-9. (Pubitemid 40223713)
139. Suzuki J, Suzuki S, Okubo T. Effects of fenoterol on inspiratory effort sensation and fatigue during inspiratory threshold loading. J Appl Physiol 1996; 80: 727-733. (Pubitemid 26087231)
140. Hatipoǧlu U, Laghi F, Tobin MJ. Does inhaled albuterol improve diaphragmatic contractility in patients with chronic obstructive pulmonary disease? Am J Respir Crit Care Med 1999; 160: 1916-1921.
141. O'Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in patients with COPD. Eur Respir J 2004; 23: 832-840. (Pubitemid 38807355)
142. Powrie DJ, Wilkinson TM, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007; 30: 472-478. (Pubitemid 351182070)
143. Aubier M, De Troyer A, Sampson M, et al. Aminophylline improves diaphragmatic contractility. N Engl J Med 1981; 305: 249-252.
144. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003; 167: 813-818. (Pubitemid 36801766)
145. Rahman I. Pharmacological antioxidant strategies as therapeutic interventions for COPD. Biochim Biophys Acta 2012; 1822: 714-728.
146. Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. Int J Chron Obstruct Pulmon Dis 2011; 6: 413-421.
147. Djekic UV, Gaggar A, Weathington NM. Attacking the multitiered proteolytic pathology of COPD: new insights from basic and translational studies. Pharmacol Ther 2009; 121: 132-146.
148. Lucas SD, Costa E, Guedes RC, et al. Targeting COPD: advances on low-molecular-weight inhibitors of human neutrophil elastase. Med Res Rev 2011 [Epub ahead of print DOI: 10.1002/med.20247].
149. Groutas WC, Dou D, Alliston KR. Neutrophil elastase inhibitors. Expert Opin Ther Pat 2011; 21: 339-354.
150. Kuna P, Jenkins M, O'Brien CD, et al. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. Respir Med 2012; 106: 531-539.
151. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946. (Pubitemid 38807371)
152. Churg A, Cosio M, Wright JL. Mechanisms of cigarette smoke-induced COPD: insights from animal models. Am J Physiol Lung Cell Mol Physiol 2008; 294: L612-L631. (Pubitemid 351520094)
153. Martinez FJ, Donohue JF, Rennard SI. The future of chronic obstructive pulmonary disease treatment - difficulties of and barriers to drug development. Lancet 2011; 378: 1027-1037.